NCT04422899View on ClinicalTrials.gov

Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

September 29, 2021

Study Completion Date

February 28, 2022

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

AIV007

intravitreal

Trial Locations (2)

79606

Retina Research Institute of Texas, Abilene

92647

Salehi Retina Institute, Huntington Beach

Sponsors
All Listed Sponsors
lead

AiViva BioPharma, Inc.

INDUSTRY

NCT04422899 - Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter